Comparison of single/pooled CTCs and bulk exome sequencing
Single cell technologies allow the interrogation of tumor heterogeneity, providing insights into tumor evolution and treatment resistance. To better understand whether circulating tumor cells (CTCs) could complement metastatic biopsies for tumor genomic profiling, we characterized 11 single CTCs and 10 pooled CTC samples at the mutational and copy number aberration (CNA) levels, and compared these results with matched synchronous tumor biopsies from 3 metastatic breast cancer patients with triple-negative (TNBC), HER2-positive and estrogen receptor-positive (ER+) tumors. Similar CNA profiles and the same patient-specific driver mutations were found in bulk tissue and CTCs for the HER2-positive and TNBC tumors, whereas different CNA profiles and driver mutations were identified for the ER+ tumor, which presented two distinct clones in CTCs defined by mutations in ESR1 Y537N and TP53, respectively. Furthermore, de novo mutational signatures derived from CTCs described patient-specific biological processes. These data suggest that tumor tissue and CTCs provide complementary clinically relevant information to map tumor heterogeneity and tumor evolution.
- 30 samples
- DAC: EGAC00001002254
- Technology: Illumina HiSeq 2000
Access policy for Circulating tumor cells DNA sequencing from breast cancer
DATA ACCESS AGREEMENT These terms and conditions govern access to the managed access dataset to which the User has requested access. The User agrees to be bound by these terms and conditions. Definitions: Data means all and any human genetic data obtained from this study/dataset. User means a researcher who has previously completed the Data Access Agreement. User Institution means the organisation at which the User is employed, affiliated or enrolled. Publications means, without limitation, articles published in print journals, electronic journals, reviews, books, posters and other written and verbal presentations of research. Terms and Conditions: In signing this Agreement: You agree to use the Data only for research purposes. You agree to preserve, at all times, the confidentiality of information and Data. You agree not to transfer or disclose the Data, in whole or part, or any identifiable material derived from the Data, to others, except as necessary for data/safety monitoring or programme management. Should You wish to share the Data with a collaborator outwith the same Institution, the third party must make a separate application for access to the Data. You agree to use the data for the approved purpose and project described in your application; use of the data for a new purpose or project will require a new application and approval. You agree to acknowledge in any work based in whole or part on the Data, the published paper from which the Data derives. You understand and acknowledge that the Data is protected by copyright and other intellectual property rights, and that duplication, except as reasonably required to carry out Your research with the Data, or sale of all or part of the Data on any media is not permitted. You recognise that nothing in this agreement shall operate to transfer to the User Institution any intellectual property rights relating to the Data. You accept that this agreement will terminate immediately upon any breach of this agreement by You and You will be required to destroy any Data held.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |